Guideline Central Blog

September is Prostate Cancer Awareness Month. Prostate cancer is the second most common cancer among men, and 1 in 9 men will be diagnosed with prostate cancer during their lifetime. Prostate cancer is the leading site of new cancers diagnosed and the number two cause of death for males.

For Prostate Cancer Awareness Month 2023 we will be taking a closer look at the current clinical practice guidelines for prostate cancer and related topics.

Prostate Cancer – Clinical Practice Guidelines:

• Prostate Cancer
  • National Comprehensive Cancer Network (NCCN) – Published August 2023

• Advanced Prostate Cancer
  • American Urological Association (AUA); Society of Urologic Oncology (SUO) – Published April 25, 2023

• Early Detection of Prostate Cancer
  • American Urological Association (AUA); Society of Urologic Oncology (SUO) – Published April 25, 2023

• Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer
  • American Society of Clinical Oncology (ASCO) – Published April 4, 2023

• Clinically Localized Prostate Cancer: Introduction, Risk Assessment, Staging and Risk-Based Management
  • American Society for Radiation Oncology (ASTRO); American Urological Association (AUA) – Published May 10, 2022

• Clinically Localized Prostate Cancer: Radiation and Future Directions
  • American Society for Radiation Oncology (ASTRO); American Urological Association (AUA) – Published May 10, 2022

• Clinically Localized Prostate Cancer: Active Surveillance, Surgery and Follow-up
  • American Society for Radiation Oncology (ASTRO); American Urological Association (AUA) – Published May 10, 2022

• Optimum Imaging Strategies for Advanced Prostate Cancer
  • American Society of Clinical Oncology (ASCO) – Published January 15, 2020

• Bone Health and Bone-Targeted Therapies for Prostate Cancer
  • American Society of Clinical Oncology (ASCO) – Published February 19, 2020

• Molecular Biomarkers in Localized Prostate Cancer
  • American Society of Clinical Oncology (ASCO) – Published December 12, 2019

• Hypofractionated Radiation Therapy for Localized Prostate Cancer
  • American Urological Association (AUA) – Published October 1, 2018

• Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer
  • American Society of Clinical Oncology (ASCO) – Published April 2, 2018

• Brachytherapy for Patients with Prostate Cancer
  • American Society of Clinical Oncology (ASCO) – Published March 28, 2017

• Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer
  • American Society of Clinical Oncology (ASCO) – Published April 25, 2017

• Castration-Resistant Prostate Cancer
  • American Urological Association (AUA) – Published December 1, 2018

• Clinically Localized Prostate Cancer
  • American Society for Radiation Oncology (ASTRO); American Urological Association (AUA); Society of Urologic Oncology (SUO) – Published March 1, 2018

• Immunotherapy for the Treatment of Prostate Carcinoma
  • Society for Immunotherapy of Cancer (SITC) – Published December 20, 2016

Prostate Cancer – Medications:

There have been three major new FDA approvals for prostate cancer diagnostics and treatments since the beginning of 2023:

• Akeega (niraparib and abiraterone acetate) – Janssen (August 2023)
  • Treatment of adult patients with deleterious or suspected deleterious BRCA-positive mCRPC, as detected by an FDA-approved test.
• Lynparza (olaparib) – AstraZeneca / Merck (June 2023) – New Indication
  • Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC).
• Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) – Telix Pharmaceuticals (March 2023) – Expanded Indication
  • For the selection of patients with metastatic prostate cancer, for whom Lu 177 PSMA-directed therapy is indicated.

Looking Ahead:

As we look ahead towards National Prostate Cancer Awareness Month 2024, there will be multiple focused updates to existing Prostate Cancer clinical guidelines, as well as a few new guidelines.

• ASCO Germline Mutation Testing in Prostate Cancer – UPDATE
• ASCO Metastatic Systemic Castration-Resistant Prostate Cancer – UPDATE
• ASCO Primary Tumor-Directed and Metastasis-Directed Local Therapy in Metastatic Prostate Cancer
• ASCO Genitourinary Cancers Survivorship
• ASCO Special Considerations for Elderly Patients with Genitourinary Cancers
• NCCN Prostate Cancer

That’s it for our recap of this year’s Prostate Cancer Awareness Month 2023. Did we miss anything? If so, let us know. Also let us know which awareness month you’d like to see us cover next in our ongoing series.